LGND
Ligand Pharmaceuticals Incorporated
306.80$
+1.3%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +2.3% | +16.1% | -5.2% | +10.2% | -1.4% | -3.9% | +4.8% | +55.7% | +5.7% | -1.8% | +42.7% | |
| – | -6.5% | +55.4% | -15.4% | -0.9% | +7.2% | -6.7% | +14.1% | +113.6% | +10.4% | +4.0% | +68.4% | |
| – | +19.1% | +118.2% | -63.8% | +250.7% | +13.7% | -33.6% | +41.0% | +106.0% | +25.5% | -34.2% | +774.8% | |
| – | -10.6% | +82.4% | -26.9% | -3.2% | +16.6% | -18.5% | +22.2% | +160.3% | +10.4% | +6.3% | +74.2% | |
| – | +9.2% | -27.7% | +31.8% | +12.4% | +0.8% | +0.9% | -1.7% | +37.9% | +5.1% | -10.2% | +27.6% | |
| – | -5.6% | -11.0% | -32.2% | -7.1% | +5.0% | -16.3% | +9.1% | -7.7% | -23.3% | +45.4% | -22.6% | |
| – | -0.4% | +1.8% | +0.0% | +0.0% | +0.0% | -3.5% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -6.8% | -2.7% | -2.8% | -2.9% | -3.0% | -3.1% | -3.2% | -6.6% | +80.8% | -2.7% | -49.1% | |
| – | -14.8% | +24.4% | -15.0% | +24.6% | -2.1% | -1.3% | +9.3% | +338.6% | +3.2% | -1.6% | +127.8% | |
| – | +6.7% | +6.2% | +4.2% | +33.4% | +49.8% | +58.1% | +10.3% | -52.8% | +22.6% | +8.6% | +14.9% | |
| – | -17.5% | +144.6% | +16.5% | -6.7% | +18.3% | -31.6% | +26.0% | -2.2% | +0.6% | -0.6% | -0.6% | |
| – | -1.9% | -22.0% | -5.3% | +161.8% | +11.5% | +2.5% | +60.0% | +223.4% | -88.3% | +62.6% | +78.7% | |
| – | – | – | – | – | – | – | – | – | +0.2% | +0.2% | +152.1% | |
| – | +4.9% | +15.1% | -3.9% | +8.5% | -1.3% | -4.2% | +4.1% | +14.7% | +7.1% | -2.0% | -3.0% | |
| – | +3.8% | +17.1% | -8.8% | -1.3% | -5.9% | -8.5% | +1.1% | +25.3% | +5.2% | -2.2% | -1.9% | |
| – | +1.7% | +2.5% | -0.5% | +2.2% | +3.0% | +1.1% | +3.8% | +1.2% | +4.8% | -5.9% | +9.8% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.